RESUMEN
Neuromuscular diseases are characterized by progressive muscle degeneration and muscle weakness resulting in functional disabilities. While each of these diseases is individually rare, they are common as a group, and a large majority lacks effective treatment with fully market approved drugs. Magnetic resonance imaging and spectroscopy techniques (MRI and MRS) are showing increasing promise as an outcome measure in clinical trials for these diseases. In 2013, the European Union funded the COST (co-operation in science and technology) action BM1304 called MYO-MRI (www.myo-mri.eu), with the overall aim to advance novel MRI and MRS techniques for both diagnosis and quantitative monitoring of neuromuscular diseases through sharing of expertise and data, joint development of protocols, opportunities for young researchers and creation of an online atlas of muscle MRI and MRS. In this report, the topics that were discussed in the framework of working group 3, which had the objective to: Explore new contrasts, new targets and new imaging techniques for NMD are described. The report is written by the scientists who attended the meetings and presented their data. An overview is given on the different contrasts that MRI can generate and their application, clinical needs and desired readouts, and emerging methods.
Asunto(s)
Medios de Contraste , Imagen por Resonancia Magnética/métodos , Espectroscopía de Resonancia Magnética/métodos , Músculos/diagnóstico por imagen , Enfermedades Neuromusculares/diagnóstico por imagen , Animales , Enfermedades de los Perros/diagnóstico por imagen , Perros , Unión Europea , Humanos , Enfermedades Neuromusculares/veterinariaRESUMEN
INTRODUCTION: Magnetic resonance imaging (MRI) shows slight spatial variations in brain white matter (WM). We used quantitative multi-parametric MRI to evaluate in what respect these inhomogeneities could correspond to WM subtypes with specific characteristics and spatial distribution. MATERIALS AND METHODS: Twenty-six controls (12 women, 38 ±9 Y) took part in a 60-min session on a 3T scanner measuring 7 parameters: R1 and R2, diffusion tensor imaging which allowed to measure Axial and Radial Diffusivity (AD, RD), magnetization transfer imaging which enabled to compute the Macromolecular Proton Fraction (MPF), and a susceptibility-weighted sequence which permitted to quantify R2* and magnetic susceptibility (χm). Spatial independent component analysis was used to identify WM subtypes with specific combination of quantitative parameters values. RESULTS: Three subtypes could be identified. t-WM (track) mostly mapped on well-formed projection and commissural tracts and came with high AD values (all p < 10(-18)). The two other subtypes were located in subcortical WM and overlapped with association fibers: f-WM (frontal) was mostly anterior in the frontal lobe whereas c-WM (central) was underneath the central cortex. f-WM and c-WM had higher MPF values, indicating a higher myelin content (all p < 1.7 10(-6)). This was compatible with their larger χm and R2, as iron is essentially stored in oligodendrocytes (all p < 0.01). Although R1 essentially showed the same, its higher value in t-WM relative to c-WM might be related to its higher cholesterol concentration. CONCLUSIONS: Thus, f- and c-WMs were less structured, but more myelinated and probably more metabolically active regarding to their iron content than WM related to fasciculi (t-WM). As known WM bundles passed though different WM subtypes, myelination might not be uniform along the axons but rather follow a spatially consistent regional variability. Future studies might examine the reproducibility of this decomposition and how development and pathology differently affect each subtype.
Asunto(s)
Imagen de Difusión Tensora , Imagen por Resonancia Magnética , Sustancia Blanca/diagnóstico por imagen , Adulto , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Skeletal muscle inflammation/necrosis and fat infiltration are strong indicators of disease activity and progression in many neuromuscular disorders. They can be assessed by muscle T2 relaxometry and water-fat separation techniques, respectively. In the present work, we exploited differences between water and fat T1 and T2 relaxivities by applying a bi-component extended phase graph (EPG) fitting approach to simultaneously quantify the muscle water T2 and fat fraction from standard multi-slice multi-echo (MSME) acquisitions in the presence of stimulated echoes. Experimental decay curves were adjusted to the theoretical model using either an iterative non-negative least-squares (NNLS) procedure or a pattern recognition approach. Twenty-two patients (age, 49 ± 18 years) were selected to cover a large range of muscle fat infiltration. Four cases of chronic or subchronic juvenile dermatomyositis (age, 8 ± 3 years) were investigated before and 3 months following steroid treatment. For control, five healthy volunteers (age, 25 ± 2 years) were recruited. All subjects underwent the MSME sequence and EPG fitting procedure. The EPG fitting algorithm allowed a precise estimation of water T2 and fat fraction in diseased muscle, even in the presence of large B1(+) inhomogeneities. In the whole cohort of patients, there was no overall correlation between water T2 values obtained with the proposed method and the fat fraction estimated inside muscle tissues (R(2) = 0.02). In the patients with dermatomyositis, there was a significant decrease in water T2 (-4.09 ± 3.7 ms) consequent to steroid treatment. The pattern recognition approach resulted in a 20-fold decrease in processing time relative to the iterative NNLS procedure. The fat fraction derived from the EPG fitting approach correlated well with the fat fraction derived from a standard three-point Dixon method (≈1.5% bias). The bi-component EPG fitting analysis is a precise tool to monitor muscle tissue disease activity and is able to handle bias introduced by fat infiltration and B1(+) inhomogeneities.
Asunto(s)
Tejido Adiposo/metabolismo , Imagen por Resonancia Magnética/métodos , Músculo Esquelético/metabolismo , Agua/metabolismo , Adulto , Algoritmos , Niño , Femenino , Humanos , Inflamación/patología , Masculino , Persona de Mediana Edad , MusloRESUMEN
BACKGROUND: Outcome measures for clinical trials in neuromuscular diseases are typically based on physical assessments which are dependent on patient effort, combine the effort of different muscle groups, and may not be sensitive to progression over short trial periods in slow-progressing diseases. We hypothesised that quantitative fat imaging by MRI (Dixon technique) could provide more discriminating quantitative, patient-independent measurements of the progress of muscle fat replacement within individual muscle groups. OBJECTIVE: To determine whether quantitative fat imaging could measure disease progression in a cohort of limb-girdle muscular dystrophy 2I (LGMD2I) patients over a 12 month period. METHODS: 32 adult patients (17 male;15 female) from 4 European tertiary referral centres with the homozygous c.826C>A mutation in the fukutin-related protein gene (FKRP) completed baseline and follow up measurements 12 months later. Quantitative fat imaging was performed and muscle fat fraction change was compared with (i) muscle strength and function assessed using standardized physical tests and (ii) standard T1-weighted MRI graded on a 6 point scale. RESULTS: There was a significant increase in muscle fat fraction in 9 of the 14 muscles analyzed using the quantitative MRI technique from baseline to 12 months follow up. Changes were not seen in the conventional longitudinal physical assessments or in qualitative scoring of the T1w images. CONCLUSIONS: Quantitative muscle MRI, using the Dixon technique, could be used as an important longitudinal outcome measure to assess muscle pathology and monitor therapeutic efficacy in patients with LGMD2I.
Asunto(s)
Progresión de la Enfermedad , Imagen por Resonancia Magnética , Músculos/patología , Distrofia Muscular de Cinturas/diagnóstico , Distrofia Muscular de Cinturas/patología , Tejido Adiposo/metabolismo , Adolescente , Adulto , Femenino , Estudios de Seguimiento , Humanos , Interpretación de Imagen Asistida por Computador , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
Although muscular dystrophies are among the most common human genetic disorders, there are few treatment options available. Animal models have become increasingly important for testing new therapies prior to entering human clinical trials. The Dmd(mdx) mouse is the most widely used animal model for Duchenne muscular dystrophy (DMD), presenting the same molecular and protein defect as seen in humans with the disease. However, this mouse is not useful for clinical trials because of its very mild phenotype. The mouse model for congenital myodystrophy type 1D, Large(myd), harbors a mutation in the glycosyltransferase Large gene and displays a severe phenotype. To help elucidate the role of the proteins dystrophin and LARGE in the organization of the dystrophin-glycoprotein complex in muscle sarcolemma, we generated double-mutant mice for the dystrophin and LARGE proteins. The new Dmd(mdx)/Large(myd) mouse model is viable and shows a severe phenotype that is associated with the lack of dystrophin in muscle. We tested the usefulness of our new mouse model for cell therapy by systemically injecting them with normal murine mesenchymal adipose stem cells (mASCs). We verified that the mASCs were hosted in the dystrophic muscle. The new mouse model has proven to be very useful for the study of several other therapies, because injected cells can be screened both through DNA and protein analysis. Study of its substantial muscle weakness will also be very informative in the evaluation of functional benefits of these therapies.
Asunto(s)
Modelos Animales de Enfermedad , Distrofia Muscular Animal/fisiopatología , Distrofia Muscular Animal/terapia , Enfermedades Neuromusculares/fisiopatología , Enfermedades Neuromusculares/terapia , Tejido Adiposo/citología , Animales , ADN/metabolismo , Distrofina/metabolismo , Femenino , Humanos , Imagenología Tridimensional , Masculino , Trasplante de Células Madre Mesenquimatosas , Células Madre Mesenquimatosas/citología , Ratones , Ratones Endogámicos mdx , Distrofia Muscular Animal/patología , Enfermedades Neuromusculares/patología , FenotipoAsunto(s)
Guías como Asunto/normas , Imagen por Resonancia Magnética/métodos , Imagen por Resonancia Magnética/normas , Músculo Esquelético/patología , Enfermedades Musculares/diagnóstico , Francia , Humanos , Procesamiento de Imagen Asistido por Computador/métodos , Procesamiento de Imagen Asistido por Computador/normas , Evaluación de Resultado en la Atención de Salud , SueciaRESUMEN
PURPOSE: To measure regional T(1) changes in the postnatal rat brain following systemic administration of the contrast agent manganese chloride (MnCl(2)). MATERIALS AND METHODS: MnCl(2) (120 mM) was administered intravenously (i.v.) at 1.25 mL/hour to a dose of 175 mg/kg body weight. MRI experiments were performed on anaesthetized animals (32 male Wistar rats, postnatal days (PDs) 11, 16, 21, and 31) at 2.0 T. Regions of interest (ROIs) were drawn in sagittal slices and placed over five brain regions: olfactory bulb, cerebellum, cortex, thalamus, and hypothalamus. The signal intensities of each ROI were measured and fitted to a three-parameter function to estimate T(1) values. RESULTS: In the brains of animals who did not receive the contrast agent (control group), we observed a consistent age-dependent decrease in T(1) values. In the brains of manganese-infused animals (manganese group), however, T(1) values were significantly lower than in the control group, indicating the uptake of manganese, but no dependence of T(1) on age was found. CONCLUSION: Our T(1) measurements indicate that the relative Mn(2+) concentrations are higher in neonates and decrease with brain development. An estimate of the relative cortical concentration of manganese shows a two-fold drop from PD 11 to PD 31.
Asunto(s)
Mapeo Encefálico/métodos , Encéfalo/crecimiento & desarrollo , Cloruros/farmacocinética , Medios de Contraste/farmacocinética , Imagen por Resonancia Magnética/métodos , Compuestos de Manganeso/farmacocinética , Análisis de Varianza , Animales , Animales Recién Nacidos , Cloruros/administración & dosificación , Medios de Contraste/administración & dosificación , Aumento de la Imagen , Infusiones Intravenosas , Masculino , Compuestos de Manganeso/administración & dosificación , Ratas , Ratas WistarRESUMEN
Magnetic resonance imaging is employed to study water ingress in fine zeolite powders compacted by high pressure. The experimental conditions are chosen such that the applicability of Boltzmann's transformation of the one-dimensional diffusion equation is approximately satisfied. The measured moisture profiles indicate subdiffusive behavior with a spatiotemporal scaling variable eta=x/t(gamma/2) (0